(S1 (S (S (NP (NN Phosphoinositide) (NN 3-kinase)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NP (JJ high) (JJ glucose-induced) (NN hypertrophy)) (CC and) (NP (NN p21WAF1) (NN expression))) (PP (IN in) (NP (NN LLC-PK1) (NNS cells)))))))) (. .)))
(S1 (S (S (NP (NP (NP (VBG Transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (, ,) (NP (NN Smads)) (, ,) (CC and) (NP (DT the) (NP (NP (JJ cyclin-dependent) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN cdk)) (-RRB- -RRB-))) (NN inhibitor) (NN p21-LRB-WAF1-RRB-))) (VP (VBP are) (ADJP (JJ important) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ diabetic) (JJ tubular) (NN hypertrophy)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Phosphoinositide) (CD 3) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-))) (NN /Akt) (NN kinase) (NN activity)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (JJ diabetic) (JJ glomerular) (NN hypertrophy)))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN PI3K))) (PP (IN in) (NP (NP (ADJP (NP (NP (JJ high) (NN glucose)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mM)) (-RRB- -RRB-))) (JJ -induced)) (NN p21-LRB-WAF1-RRB-)) (, ,) (NP (NN Smad2/3)) (, ,) (CC and) (NP (NP (ADJP (NN cell) (JJ cycle-dependent)) (NN hypertrophy)) (PP (IN in) (NP (NN LLC-PK1) (NNS cells))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (JJ high) (NN glucose)) (ADVP (ADVP (RB time-dependently)) (PRN (-LRB- -LRB-) (NP (CD 1-48) (NN h)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NN PI3K/Akt) (NN kinase) (NN activity))))))) (. .)))
(S1 (S (S (NP (NP (NN LY294002)) (PRN (-LRB- -LRB-) (NP (DT a) (NN PI3K) (NN inhibitor)) (-RRB- -RRB-))) (VP (VBD attenuated) (NP (ADJP (ADJP (JJ high) (JJ glucose-induced) (NN cell) (JJ cycle-dependent)) (PRN (-LRB- -LRB-) (NP (NN G-LRB-0-RRB-/G-LRB-1-RRB-) (NN phase)) (-RRB- -RRB-))) (NN hypertrophy)) (PP (IN at) (NP (CD 72) (NN h))) (SBAR (IN while) (S (VP (VBG attenuating) (NP (NP (JJ high) (JJ glucose-induced) (NN p21-LRB-WAF1-RRB-) (NN gene) (NN transcription)) (CC and) (NP (NN protein) (NN expression))) (PP (IN at) (NP (CD 36-48) (NN h)))))))) (. .)))
(S1 (S (S (NP (NN LY294002)) (ADVP (RB also)) (VP (VBD attenuated) (NP (NP (JJ high) (JJ glucose-induced) (NN binding)) (PP (IN of) (NP (NN p21-LRB-WAF1-RRB-))) (PP (TO to) (NP (DT the) (NN cyclin) (NN E/cdk2) (NN complex)))) (, ,) (SBAR (IN whereas) (S (VP (VBG attenuating) (NP (NP (JJ high) (JJ glucose-induced) (NN TGF-beta) (NN bioactivity)) (, ,) (NP (NN Smad2/3) (NN phosphorylation)) (, ,) (CC and) (NP (NN Smad2/3) (JJ DNA-binding) (NN activity))) (PP (IN at) (NP (CD 36-48) (NN h)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD concluded) (SBAR (IN that) (S (NP (NN PI3K)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (JJ high) (JJ glucose-induced) (ADJP (NN cell) (JJ cycle-dependent)) (NN hypertrophy)) (, ,) (NP (NN p21-LRB-WAF1-RRB-) (NN transcription)) (CC and) (NP (NP (NP (NN expression)) (, ,) (NP (NP (JJ p21-LRB-WAF1-RRB-) (NN binding)) (PP (TO to) (NP (DT the) (NN cyclin) (NN E/cdk2) (NN complex)))) (, ,) (NP (NN TGF-beta) (NN bioactivity)) (, ,) (CC and) (NP (NN Smad2/3) (NN activity))) (PP (IN in) (NP (NN LLC-PK1) (NNS cells)))))))))))) (. .)))
